Cadrenal TherapeuticsCVKD
13F holders, Q2 2026 (June 30)16holders −1
5new positions
6sold out
$3.34avg. 13F price*
At the end of Q2 2026, 16 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, down 1 from Q1 2026. 5 opened new positions and 6 sold out. The largest holders were Vanguard Capital Management LLC ($167K), HRT Financial LP ($97K) and Geode Capital Management, LLC ($64K).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $104K |
| Exits | 6 | $69K |
All 13F filers, Q1 2026 → Q2 2026: 38,718 shares bought and 17,292 shares sold, net +21,426 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Vanguard Capital Management LLC | 0.00% | Add +10.9% | 50,137 | $167K |
| HRT Financial LP | 0.00% | New | 29,055 | $97K |
| Geode Capital Management, LLC | 0.00% | Reduce -12.0% | 19,024 | $64K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 8,311 | $28K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +226.2% | 1,282 | $4K |
| UBS Group AG | 0.00% | Add +36966.7% | 1,112 | $4K |
| Grove Bank & Trust | 0.00% | New | 1,000 | $3K |
| Morgan Stanley | 0.00% | Add +606.0% | 706 | $2K |
| Clearstead Advisors, LLC | 0.00% | New | 650 | $2K |
| Quest 10 Wealth Builders, Inc. | 0.00% | New | 380 | $1K |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $1K |
| Rockefeller Capital Management L.P. | 0.00% | No change | 150 | $501 |
| Wells Fargo & Company | 0.00% | No change | 99 | $331 |
| Barclays PLC | 0.00% | New | 93 | $311 |
| Archer Investment Corp | 0.00% | No change | 35 | $117 |
| IFP Advisors, Inc | 0.00% | No change | 30 | $100 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.